Recombinant Aav
Recombinant Aav - Related Videos
02:44
Generation of Recombinant Adeno-Associated Virus Through Plasmid Transfection
0 Views •
2026
Source: Ding, J., et al. Preparation of rAAV9 to Overexpress or Knockdown Genes in Mouse Hearts. J. Vis. Exp. (2016)This video demonstrates the production of recombinant adeno-associated virus particles through plasmid transfection in mammalian cells. It highlights the coordinated expression of Rep, Cap, and helper proteins that drive viral genome replication and capsid assembly within the nucleus.
21:55
Engineering and Evolution of Synthetic Adeno-Associated Virus (AAV) Gene Therapy Vectors via DNA Family Shuffling
0 Views •
Cited by 35 •
2012
We demonstrate the basic technique to molecularly engineer and evolve synthetic Adeno-associated viral (AAV) gene therapy vectors via DNA family shuffling. Moreover, we provide general guidelines and representative examples for selection and analysis of individual chimeric capsids with enhanced properties on target cells in culture or in mice.
04:54
Cell-Based AAV Neutralizing Antibody Assay: A Colorimetric Technique to Detect Neutralizing Antibodies Against Specific Adeno-Associated Viruses in Serum
0 Views •
2025
In this video, we demonstrate an in vitro colorimetric assay to detect the presence of neutralizing antibodies against alkaline phosphatase-expressing recombinant adeno-associated virus serotype 6 (rAAV6) vectors in sheep serum samples. The assay utilizes the reaction between the AAV encoding a human placental alkaline phosphatase gene and its substrate to generate an insoluble purple product.
08:35
Production and Titering of Recombinant Adeno-associated Viral Vectors
0 Views •
Cited by 149 •
2011
Recombinant adeno-associated virus (rAAVs) vectors are becoming increasingly valuable for in vivo studies in animals. We describe how rAAVs can be produced in the laboratory and how these vectors can be titered to give an accurate reading of the number of infectious particles produced.
14:23
Recombineering Homologous Recombination Constructs in Drosophila
0 Views •
Cited by 9 •
2013
Homologous recombination techniques greatly advance Drosophila genetics by enabling the creation of molecularly precise mutations. The recent adoption of recombineering allows one to manipulate large pieces of DNA and transform them into Drosophila6. The methods presented here combine these techniques to rapidly generate large homologous recombination vectors.
FAQs
The engineered genome retains AAV inverted terminal repeats, or ITRs, while the viral replication and capsid genes are replaced by a therapeutic or experimental transgene. This arrangement allows the genetic payload to be packaged without carrying the genes needed to produce a replication-competent virus. The design therefore separates genome packaging from viral replication functions.
Following cell entry, the vector releases its genome inside the target cell. The genetic material commonly persists as episomal DNA, meaning it remains outside the cell’s chromosomes, and can support expression of the delivered transgene. This intracellular behavior helps researchers study gene function or produce a desired genetic effect in the targeted tissue.
Capsid serotype and delivery route are major determinants of which tissues receive the vector. The capsid contributes to tissue targeting, while the route determines how the vector reaches cells in the body or experimental system. Consequently, selecting these features is central to directing transgene delivery toward a particular tissue rather than treating targeting as a property of the transgene alone.
Removing replication and capsid genes prevents the packaged vector genome from containing the viral functions required to generate new virus particles. At the same time, retaining the inverted terminal repeats preserves key AAV genome features needed for vector construction and packaging. This separation supports delivery of an experimental or therapeutic sequence without encoding a replication-competent virus.
Planning begins by choosing the experimental or therapeutic transgene and placing it within an AAV-derived genome that retains inverted terminal repeats. Researchers then consider the capsid serotype and delivery route because these influence tissue targeting. The resulting design connects the genetic payload with the intended target cells and the biological question, whether gene function or inherited disease treatment.
Researchers use Recombinant AAV when they need to deliver genetic material into target cells to examine gene function. Because the vector can support transgene expression after its genome persists as episomal DNA, it provides a way to investigate the effects of an introduced sequence in selected tissues. Capsid and delivery choices help align the experiment with its target.
In inherited-disorder research, rAAV can carry a therapeutic transgene into target cells, where the delivered genome may support expression of that sequence. The approach is relevant to both experimental treatment development and molecular studies of disease-related gene function. Tissue targeting remains important, since capsid serotype and delivery route influence where the genetic material is delivered.
An rAAV study can provide information about the effect of a delivered transgene in target cells or tissues. Investigators may use the resulting transgene expression to study gene function, while therapeutic studies can evaluate whether delivery supports development of an approach for an inherited disorder. Interpretation depends on the selected payload, capsid serotype, and delivery route.